Medifoxamine

CHEMBL85231 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

257.3 g/mol

LogP

3.8

Phase

4

This antidepressant was investigated in France for its ability to inhibit the reuptake of dopamine and serotonin, potentially offering a novel mechanism for treating depression. It did not receive widespread approval.

分子量

257.3300 g/mol

LogP

3.80

TPSA

21.70 Å²

リピンスキーの五則

適合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CC(Oc1ccccc1)Oc1ccccc1

InChI

InChI=1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3

Molecular Formula

C16H19NO2

HBD / HBA

- / 3

回転可能結合数

6

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This antidepressant was investigated in France for its ability to inhibit the reuptake of dopamine and serotonin, potentially offering a novel mechanism for treating depression. It did not receive widespread approval.

Yes, Medifoxamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL85231. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 36109. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Medifoxamine PillFYIで

構造

クイックデータ

分子式: C16H19NO2

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.